Peptides DB
Research-centric peptide and protocol reference hub

CJC-1295 vs Semaglutide

Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team

CJC-1295: Research use — not FDA-approvedSemaglutide: FDA-approved

A data-driven comparison of CJC-1295 and Semaglutide (also searched as Semaglutide vs CJC-1295) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

CJC-1295 centers on muscle, while Semaglutide leans toward metabolic. On indexed research, Semaglutide is ahead (CJC-1295: 11 studies, Human clinical; Semaglutide: 57, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • CJC-1295 is strongest for muscle; Semaglutide for metabolic.
  • Evidence: CJC-1295 Human clinical (11 studies) vs Semaglutide Human clinical (57).
  • Check the FDA-approval status chips above before assuming a legal use pathway.

Effect profiles, overlaid

CJC-1295Semaglutide

At a glance

CJC-1295Human clinical

GHRH analogue | GH/IGF-1 modulation

Strongest: MuscleStudies: 11Level: Limited Research
SemaglutideHuman clinical

GLP-1 Agonist | Type 2 Diabetes and Obesity Management

Strongest: MetabolicStudies: 57Level: FDA Approved

CJC-1295 vs Semaglutide: side-by-side

MetricCJC-1295Semaglutide
ClassMuscleMetabolic
Regulatory statusResearch use onlyFDA-approved
Evidence gradeHuman clinicalHuman clinical
Studies indexed1157
Research levelLimited ResearchFDA Approved
Strongest effectMuscle & body compMetabolic & appetite
Healing & recovery3.01.0
Muscle & body comp4.01.0
Metabolic & appetite3.05.0
Neuro & mood2.02.0
Sleep & circadian3.01.0
Inflammation & immune2.01.0
Skin & aesthetics2.03.0

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyCJC-1295Semaglutide
MechanismGHRH (1–29) analog, modifiedGLP-1 receptor agonist
RouteSubcutaneous injectionSubcutaneous injection (oral form also available)
Half-life~30 min~7 days (≈165 h)
Time to peak1–3 days
Duration of actionWeekly dosing

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is CJC-1295?

GHRH analogue used in research contexts for GH/IGF-1 modulation, muscle and bone density, sleep, and recovery.

Full CJC-1295 profile, mechanism & studies →

What is Semaglutide?

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone involved in glucose metabolism and appetite regulation. As a GLP-1 receptor agonist, semaglutide enhances insulin secretion in response to elevated blood glucose levels, suppresses glucagon secretion, and slows gastric emptying, leading to improved glycemic control. Additionally, it promotes satiety, contributing to weight loss, which has made it a focus of research for managing both type 2 diabetes and obesity.

Full Semaglutide profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingCJC-12953.0/5 effect signal
MuscleCJC-12954.0/5 effect signal
MetabolicSemaglutide5.0/5 effect signal
NeuroEvenBoth ~2.0/5
SleepCJC-12953.0/5 effect signal
InflammationCJC-12952.0/5 effect signal
SkinSemaglutide3.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack CJC-1295 and Semaglutide?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

CJC-1295 vs Semaglutide: side effects

CJC-1295

No community-reported effects logged yet.

Semaglutide

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

CJC-1295 has 11 approved studies indexed (Human clinical), and Semaglutide has 57 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is CJC-1295 or Semaglutide better?

It depends on your goal. CJC-1295 is strongest for muscle; Semaglutide for metabolic. Semaglutide has more indexed studies (57). See the goal-by-goal breakdown above.

Is CJC-1295 or Semaglutide better for weight loss?

Semaglutide shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.

Is CJC-1295 or Semaglutide better for muscle?

CJC-1295 leads on the muscle & body-composition axis (4.0/5).

Which has more research, CJC-1295 or Semaglutide?

CJC-1295 has 11 approved studies indexed (Human clinical); Semaglutide has 57 (Human clinical). Higher counts mean more to read, not proven superiority.

Can you stack CJC-1295 and Semaglutide?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of CJC-1295 vs Semaglutide?

CJC-1295: no community-reported effects logged yet. Semaglutide: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is CJC-1295 or Semaglutide FDA-approved?

CJC-1295 is a research-use compound and is not FDA-approved. Semaglutide is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Semaglutide better than CJC-1295?

For metabolic, Semaglutide has the edge; for muscle, CJC-1295 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.